

Tsukasa Baba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7212690/publications.pdf>

Version: 2024-02-01

70
papers

3,641
citations

257101

24
h-index

138251

58
g-index

72
all docs

72
docs citations

72
times ranked

6411
citing authors

#	ARTICLE	IF	CITATIONS
1	B7-H3 Suppresses Antitumor Immunity via the CCL2â€“CCR2â€“M2 Macrophage Axis and Contributes to Ovarian Cancer Progression. <i>Cancer Immunology Research</i> , 2022, 10, 56-69.	1.6	49
2	Immunosuppressive tumor microenvironment in Uterine Serous Carcinoma via CCL7 signal with myeloid-derived suppressor cells. <i>Carcinogenesis</i> , 2022, , .	1.3	2
3	CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	48
4	Sentinel node navigation surgery in cervical cancer: a systematic review and metaanalysis. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1247-1255.	1.0	6
5	Targeting Dormant Ovarian Cancer Cells <i>In Vitro</i> and in an <i>In Vivo</i> Mouse Model of Platinum Resistance. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 85-95.	1.9	6
6	Time for enhancing government-led primary prevention of cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e12.	1.0	4
7	Survey of the clinical practice pattern of using sentinel lymph node biopsy in patients with gynecological cancers in Japan: the Japan Society of Gynecologic Oncology study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 971-979.	1.0	5
8	Tumor Immune Microenvironment during Epithelialâ€“Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2021, 27, 4669-4679.	3.2	138
9	A Novel Direct Approach to the Deep Uterine Vein in Laparoscopic Radical Hysterectomy. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 1444-1445.	0.3	0
10	Novel subtype of atonic postpartum hemorrhage: dynamic computed tomography evaluation of bleeding characteristics and the uterine cavity. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, 33, 3286-3292.	0.7	12
11	Epiploic appendage infarction of the sigmoid colon. <i>Pathology International</i> , 2020, 70, 918-919.	0.6	1
12	Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment. <i>British Journal of Cancer</i> , 2020, 122, 778-788.	2.9	61
13	Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2335.	1.8	52
14	Genome-wide analysis of microRNA to evaluate prognostic markers in isolated cancer glands and surrounding stroma in high-grade serous ovarian carcinoma. <i>Oncology Letters</i> , 2020, 20, 338.	0.8	1
15	Primary ovarian serous psammocarcinoma-a case report with mini literature review. <i>Obstetrics & Gynecology International Journal</i> , 2020, 11, 192-195.	0.0	1
16	Genome-wide analysis of microRNA to evaluate prognostic markers in isolated cancer glands and surrounding stroma in high-grade serous ovarian carcinoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	3
17	Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. <i>Medical Molecular Morphology</i> , 2019, 52, 52-59.	0.4	25
18	Primary signet ring cell carcinoma of uterine cervix and related disease: two case reports and a review. <i>International Cancer Conference Journal</i> , 2019, 8, 157-163.	0.2	5

#	ARTICLE	IF	CITATIONS
19	Acquisition of a side population fraction augments malignant phenotype in ovarian cancer. <i>Scientific Reports</i> , 2019, 9, 14215.	1.6	11
20	A New Therapeutic Strategy for Recurrent Ovarian Cancer—Bevacizumab beyond Progressive Disease. <i>Healthcare (Switzerland)</i> , 2019, 7, 109.	1.0	8
21	Immunotherapy for Uterine Cervical Cancer. <i>Healthcare (Switzerland)</i> , 2019, 7, 108.	1.0	29
22	Early feasibility surveillance of gynecologic robotic-assisted surgeries in Japan. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 787-793.	0.6	5
23	Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 1635-1647.	2.3	6
24	Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥ 80 years. <i>Surgical Oncology</i> , 2019, 29, 25-32.	0.8	1
25	Mesenteric extraovarian Sertoli-Leydig cell tumor without DICER1 hotspot mutation: a case report. <i>Diagnostic Pathology</i> , 2019, 14, 27.	0.9	4
26	VISTA expressed in tumour cells regulates T cell function. <i>British Journal of Cancer</i> , 2019, 120, 115-127.	2.9	133
27	The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e100.	1.0	9
28	Laparoscopic conservative surgery for bilateral massive ovarian edema presenting with hemoperitoneum. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2019, 35, 119-122.	0.0	0
29	Significance of venous thromboembolism in women with uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2018, 148, 267-274.	0.6	14
30	Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. <i>Nature Communications</i> , 2018, 9, 1685.	5.8	211
31	Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. <i>Journal of Surgical Oncology</i> , 2018, 117, 488-496.	0.8	15
32	Two cases of recurrent uterine cervical cancer with arterio-enteric fistula treated by femoro-femoral artery bypass in hybrid operation room. <i>International Cancer Conference Journal</i> , 2018, 7, 26-29.	0.2	1
33	Feasibility of laparoscopic surgery for obese patients with uterine corpus cancer. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2018, 34, 159-164.	0.0	0
34	Clinical utility of CA-125 in the management of uterine carcinosarcoma. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e88.	1.0	4
35	Noninvasive Positive-Pressure Ventilation for Preeclampsia-Induced Pulmonary Edema: 3 Case Reports and a Literature Review. <i>Case Reports in Obstetrics and Gynecology</i> , 2018, 2018, 1-6.	0.2	1
36	Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element. <i>Surgical Oncology</i> , 2018, 27, 433-440.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 2756-2766.	0.7	5
38	Impaired Wnt5a signaling in extravillous trophoblasts: Relevance to poor placentation in early gestation and subsequent preeclampsia. <i>Pregnancy Hypertension</i> , 2018, 13, 225-234.	0.6	13
39	Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 3676-3684.	0.7	14
40	The effect of the type of dietary protein on the development of ovarian cancer. <i>Oncotarget</i> , 2018, 9, 23987-23999.	0.8	11
41	Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 144, 329-335.	0.6	20
42	Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 145, 78-87.	0.6	31
43	Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 147, 565-571.	0.6	9
44	Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. <i>American Journal of Pathology</i> , 2017, 187, 2246-2258.	1.9	104
45	Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum. <i>BMC Cancer</i> , 2017, 17, 580.	1.1	14
46	Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e62.	1.0	4
47	Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy. <i>Medical Science Monitor</i> , 2017, 23, 826-833.	0.5	3
48	Groin lymph node detection and sentinel lymph node biopsy in vulvar cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e57.	1.0	10
49	Dual Faces of IFN γ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity. <i>Clinical Cancer Research</i> , 2016, 22, 2329-2334.	3.2	309
50	Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. <i>Gynecologic Oncology</i> , 2016, 141, 49-56.	0.6	33
51	â€Tandem balloon tamponadeâ€™ for arterial bleeding from the uterine fundus: two case reports. <i>Journal of Obstetrics and Gynaecology</i> , 2016, 36, 769-771.	0.4	5
52	Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes. <i>American Journal of Pathology</i> , 2016, 186, 1103-1113.	1.9	71
53	Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma. <i>Oncotarget</i> , 2016, 7, 54758-54770.	0.8	25
54	Suppression of <i>ABHD2</i> , identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 47620-47636.	0.8	28

#	ARTICLE	IF	CITATIONS
55	Subendometrial enhancement and peritumoral enhancement for assessing endometrial cancer on dynamic contrast enhanced MR imaging. <i>European Journal of Radiology</i> , 2015, 84, 581-589.	1.2	28
56	Safety and Antitumor Activity of Anti-“PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4015-4022.	0.8	924
57	Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-“B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 5034-5045.	0.4	439
58	Abstract A25: Dysregulation of MYC via STAT1 promotes tumor progression in serous papillary endometrial cancer. , 2015, , .		0
59	STAT1 Drives Tumor Progression in Serous Papillary Endometrial Cancer. <i>Cancer Research</i> , 2014, 74, 6519-6530.	0.4	66
60	Epigenetic and genetic dispositions of ovarian carcinomas. <i>Oncoscience</i> , 2014, 1, 574-579.	0.9	13
61	Utilization of genomic signatures to identify high-“efficacy candidate drugs for chemorefractory endometrial cancers. <i>International Journal of Cancer</i> , 2013, 133, 2234-2244.	2.3	11
62	PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction. <i>Clinical Cancer Research</i> , 2013, 19, 1363-1374.	3.2	196
63	Laparoscopic pelvic lymphadenectomy in patients with early-stage endometrial cancer. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2013, 29, 291-296.	0.0	0
64	Endometrial cancer implanted within a cesarean section scar. <i>Journal of Obstetrics and Gynaecology Research</i> , 2011, 37, 245-249.	0.6	2
65	The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. <i>Clinical Immunology</i> , 2011, 141, 338-347.	1.4	70
66	GPR54 Is a Target for Suppression of Metastasis in Endometrial Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 580-590.	1.9	37
67	Stress affects uterine receptivity through an ovarian-independent pathway. <i>Human Reproduction</i> , 2009, 24, 945-953.	0.4	45
68	Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 641-652.	2.0	144
69	Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity. <i>Biochemical and Biophysical Research Communications</i> , 2007, 360, 363-369.	1.0	13
70	Oncogenic Property of Acrogranin in Human Uterine Leiomyosarcoma: Direct Evidence of Genetic Contribution in In vivo Tumorigenesis. <i>Clinical Cancer Research</i> , 2006, 12, 1402-1411.	3.2	61